Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial
about
The safety of long-acting ß2-agonists in the treatment of stable chronic obstructive pulmonary diseaseCan the anti-inflammatory activities of β2-agonists be harnessed in the clinical setting?Relationship Between FEV1 and Patient-Reported Outcomes Changes: Results of a Meta-Analysis of Randomized Trials in Stable COPD.
P2860
Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Efficacy and safety of a fixed ...... from a 52-week Phase III trial
@ast
Efficacy and safety of a fixed ...... from a 52-week Phase III trial
@en
type
label
Efficacy and safety of a fixed ...... from a 52-week Phase III trial
@ast
Efficacy and safety of a fixed ...... from a 52-week Phase III trial
@en
prefLabel
Efficacy and safety of a fixed ...... from a 52-week Phase III trial
@ast
Efficacy and safety of a fixed ...... from a 52-week Phase III trial
@en
P2093
P2860
P356
P1476
Efficacy and safety of a fixed ...... from a 52-week Phase III trial
@en
P2093
Barbara Knorr
Carlos E Matiz-Bueno
Dennis E Doherty
Donald P Tashkin
Edward Kerwin
Heribert Staudinger
Sibabrata Banerjee
Tulin Shekar
P2860
P356
10.2147/COPD.S27319
P407
P577
2012-02-03T00:00:00Z